Response to comment on 'Clinical significance and inflammatory landscapes of a novel recurrence-associated immune signature in early-stage lung adenocarcinoma'

Affiliations

¹ Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
² Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. Electronic address: prof.jiehe@gmail.com.

Comment

Nan Sun et al. Cancer Lett. 2020.

. 2020 Dec 1:494:5-6.

doi: 10.1016/j.canlet.2020.07.033. Epub 2020 Aug 5.

¹ Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
² Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. Electronic address: prof.jiehe@gmail.com.

No abstract available

Comment on

Clinical significance and inflammatory landscapes of a novel recurrence-associated immune signature in early-stage lung adenocarcinoma.
Zhang C, Zhang Z, Zhang G, Zhang Z, Luo Y, Wang F, Wang S, Che Y, Zeng Q, Sun N, He J. Zhang C, et al. Cancer Lett. 2020 Jun 1;479:31-41. doi: 10.1016/j.canlet.2020.03.016. Epub 2020 Mar 19. Cancer Lett. 2020. PMID: 32201203
Comment on 'Clinical significance and inflammatory landscapes of a novel recurrence associated immune signature in early-stage lung adenocarcinoma'.
Chen D, Wu X, Chen Y, Chen C. Chen D, et al. Cancer Lett. 2020 Dec 1;494:17. doi: 10.1016/j.canlet.2020.07.035. Epub 2020 Aug 8. Cancer Lett. 2020. PMID: 32781014 No abstract available.